Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 16714-485

6 FDA label images from Northstar Rx Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 16714-485). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Divalproex Fig1)

Figure 1 (Divalproex Fig1)
A line graph comparing the percentage reduction in CPS rate for patients taking Divalproex Sodium Delayed-Release Tablets versus placebo. The vertical axis shows percent reduction ranging from -100% (worsening) to 100% (improvement), and the horizontal axis represents the percent of patients from 0 to 100%. Two curves illustrate the distribution of response rates for the drug and placebo groups.*
FDA Label Image

Figure 2 (Divalproex Fig2)

Figure 2 (Divalproex Fig2)
A chart showing the percent reduction in CPS rate versus percent of patients for high dose and low dose Divalproex Sodium delayed-release tablets. The vertical axis indicates percent reduction with directions for improvement or worsening, while the horizontal axis shows the percentage of patients from 0 to 100. Two lines compare outcomes for high dose (solid line) and low dose (dashed line) tablets.*
FDA Label Image

Fig-3 (Divalproex Fig3)

Fig-3 (Divalproex Fig3)
A bar chart comparing the effect of placebo and Divalproex Sodium Extended-Release Tablets. The y-axis ranges from 0 to 1.2, with values represented for placebo (0.6) and Divalproex Sodium Extended-Release Tablets (1.2). The chart highlights a statistically significant difference with p=0.006.*
FDA Label Image

Package Label-principal Display Panel (250 mg (100 Tablets Bottle))

Package Label-principal Display Panel (250 mg (100 Tablets Bottle))
Label for Divalproex Sodium Extended-Release Tablets USP 250 mg by NorthStar Rx LLC. The film-coated, extended-release oral tablets contain divalproex sodium equivalent to 250 mg valproic acid. The label includes storage instructions, dispensing guidance, manufacturer and labeler information, and a 100-tablet count.*
FDA Label Image

Package Label-principal Display Panel (500 mg (100 Tablets Bottle))

Package Label-principal Display Panel (500 mg (100 Tablets Bottle))
Divalproex Sodium Extended-Release Tablets USP 500 mg film-coated, extended-release, oral tablets. The label indicates a bottle of 100 tablets with valproic acid activity equivalent to 500 mg of divalproex sodium. The product is manufactured for NorthStar Rx LLC and bears storage instructions and usage guidance. The label has a blue, white, and brown color scheme and includes a barcode.*
FDA Label Image

Chemical Structure (Divalproex Str)

Chemical Structure (Divalproex Str)
Chemical structure diagram of Divalproex sodium, showing the molecular components and sodium ion (Na+) within the repeating unit formula.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.